Pfizer Inc., a pharmaceutical company, & biotech company, BioNTech, have recently announced the clinical results from the BNT162b2 trial, an mRNA-based COVID-19 vaccine candidate. The clinical study has apparently revealed that the vaccine is nearly 90% effective against the virus. This data is based on the 1st interim efficacy analysis conducted by an independent DMC (Data Monitoring Committee) from the Phase 3 study, which was conducted on 8th November 2020.
As per Pfizer’s statement, the vaccine candidate was more than 90% effective among participants without prior SARS-CoV-2 infection in the 1st interim efficacy analysis. BioNTech and Pfizer have become the 1st drug makers to have revealed successful clinical data from a large-scale vaccine trial. With no occurrence of serious side effects so far, the two companies are planning to seek EUA (emergency use authorization) from the U.S. FDA later this month. They also plan to submit the data for scientific peer-review publications.
In addition, the two companies are preparing to submit the necessary safety & manufacturing data to the U.S. drug regulator to examine the quality and safety of the vaccine. The company has further stated that, based on the current projections, it is planning to deliver over 50 million vaccine doses in 2020 across the globe and reach up to 1.3 billion doses in 2021.
The Phase 3 BNT162b2 trial began on 27th July with 43,538 participants, out of which, 38,955 participants have received the 2nd vaccine dose on 8th November 2020.
Dr. Albert Bourla, CEO & Chairman of Pfizer, has reportedly stated that the 1st set of trial results provides the initial evidence of the vaccine’s ability to prevent the COVID-19 disease, offering people worldwide a much-need breakthrough to end the pandemic. The company is looking forward to submitting the additional safety & efficacy data in the upcoming weeks.
Moreover, the S&P 500 recently hit a record high following the announcement about the 90% efficacy of Pfizer’s vaccine candidate.